title: Long overdue: phase II studies in older cancer patients: where does the FDA stand?
authors.forename: Lodovico
authors.initials: L
authors.lastname: Balducci
authors.forename: Jennifer
authors.initials: J
authors.lastname: Tam-McDevitt
authors.forename: Robert
authors.initials: R
authors.lastname: Hauser
authors.forename: Jody
authors.initials: J
authors.lastname: Simon
mesh_terms: D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017277:Drug Approval; D015577:Geriatric Assessment; D005853:Geriatrics; D006801:Humans; D008495:Medical Oncology; D014481:United States; D014486:United States Food and Drug Administration